{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:13:32Z","timestamp":1789794812913,"version":"4.0.1"},"reference-count":60,"publisher":"MDPI AG","issue":"21","license":[{"start":{"date-parts":[[2022,10,29]],"date-time":"2022-10-29T00:00:00Z","timestamp":1667001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA013720"],"award-info":[{"award-number":["UG1DA013720"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["2UG1DA049436"],"award-info":[{"award-number":["2UG1DA049436"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["U54GM104942"],"award-info":[{"award-number":["U54GM104942"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["UG1DA013035-09"],"award-info":[{"award-number":["UG1DA013035-09"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["2UG1DA049436-01"],"award-info":[{"award-number":["2UG1DA049436-01"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["75N95019D00013\/N01DA-19-2250"],"award-info":[{"award-number":["75N95019D00013\/N01DA-19-2250"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["75N95020D00012\/N01DA-20-2251"],"award-info":[{"award-number":["75N95020D00012\/N01DA-20-2251"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Increasing rates of overdose and overdose deaths are a significant public health problem. Research has examined co-occurring mental health conditions, including suicidality, as a risk factor for intentional and unintentional overdose among individuals with substance use disorder (SUD). However, this research has been limited to single site studies of self-reported outcomes. The current research evaluated suicidality as a predictor of overdose events in 2541 participants who use substances enrolled across eight multi-site clinical trials completed within the National Drug Abuse Treatment Clinical Trials Network between 2012 to 2021. The trials assessed baseline suicidality with the Concise Health Risk Tracking Self-Report (CHRT-SR). Overdose events were determined by reports of adverse events, cause of death, or hospitalization due to substance overdose, and verified through a rigorous adjudication process. Multivariate logistic regression was performed to assess continuous CHRT-SR score as a predictor of overdose, controlling for covariates. CHRT-SR score was associated with overdose events (p = 0.03) during the trial; the likelihood of overdose increased as continuous CHRT score increased (OR 1.02). Participants with lifetime heroin use were more likely to overdose (OR 3.08). Response to the marked rise in overdose deaths should integrate suicide risk reduction as part of prevention strategies.<\/jats:p>","DOI":"10.3390\/jcm11216400","type":"journal-article","created":{"date-parts":[[2022,10,30]],"date-time":"2022-10-30T07:26:50Z","timestamp":1667114810000},"page":"6400","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Suicidality as a Predictor of Overdose among Patients with Substance Use Disorders"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3578-0014","authenticated-orcid":false,"given":"Viviana E.","family":"Horigian","sequence":"first","affiliation":[{"name":"Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 Northwest 14th Street, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0390-0712","authenticated-orcid":false,"given":"Renae D.","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 Northwest 14th Street, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0788-5767","authenticated-orcid":false,"given":"Dikla","family":"Shmueli-Blumberg","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, 401 N. Washington St., Suite 700, Rockville, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Hefner","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, 401 N. Washington St., Suite 700, Rockville, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4206-7214","authenticated-orcid":false,"given":"Judith","family":"Feinberg","sequence":"additional","affiliation":[{"name":"Departments of Behavioral Medicine and Psychiatry & Medicine\/Infectious Diseases, West Virginia University School of Medicine, 930 Chestnut Ridge Road, Morgantown, WV 26505, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radhika","family":"Kondapaka","sequence":"additional","affiliation":[{"name":"The Emmes Company, LLC, 401 N. Washington St., Suite 700, Rockville, MD 20850, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6172-7460","authenticated-orcid":false,"given":"Daniel J.","family":"Feaster","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 Northwest 14th Street, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 Northwest 14th Street, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 Northwest 14th Street, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Davis","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Miami Miller School of Medicine, 1120 Northwest 14th Street, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-8199","authenticated-orcid":false,"given":"Rodrigo","family":"Mar\u00edn-Navarrete","sequence":"additional","affiliation":[{"name":"Division of Research and Translational Education, Centros de Integraci\u00f3n Juvenil A.C., San Jer\u00f3nimo Avenue 372, Jardines del Pedregal, Mexico City 01900, Mexico"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Tross","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, Columbia University, 1051 Riverside Drive, New York, NY 10032, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,10,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.15585\/mmwr.mm7050e3","article-title":"Trends in and Characteristics of Drug Overdose Deaths Involving Illicitly Manufactured Fentanyls\u2014United States, 2019\u20132020","volume":"70","author":"Tanz","year":"2021","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","article-title":"Methamphetamine Use, Methamphetamine Use Disorder, and Associated Overdose Deaths Among US Adults","volume":"78","author":"Han","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106729","DOI":"10.1016\/j.ypmed.2021.106729","article-title":"Polysubstance use trends and variability among individuals with opioid use disorder in rural versus urban settings","volume":"152","author":"Ellis","year":"2021","journal-title":"Prev. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41380-020-00949-3","article-title":"Polysubstance use in the U.S. opioid crisis","volume":"26","author":"Compton","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"ref_5","unstructured":"WHO (1994). Lexicon of Alcohol and Drug Terms, World Health Organization."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41398-021-01372-0","article-title":"Association of co-occurring opioid or other substance use disorders with increased healthcare utilization in patients with depression","volume":"11","author":"Vekaria","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1080\/15504263.2021.1979349","article-title":"Co-Occurring Opioid Use and Depressive Disorders: Patient Characteristics and Co-Occurring Health Conditions","volume":"17","author":"Tormohlen","year":"2021","journal-title":"J. Dual Diagn."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4088\/JCP.v67n0211","article-title":"Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: Results from the National Epidemiologic Survey on Alcohol and Related Conditions","volume":"67","author":"Conway","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3109\/00952990.2014.910519","article-title":"Co-occurring prescription opioid use problems and posttraumatic stress disorder symptom severity","volume":"40","author":"Meier","year":"2014","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Liu, S., Nwabueze, C., Pan, Y., Walter, S.M., Su, B., Xu, C., Winstanley, E.L., and Wang, K. (2021). Polysubstance Use, Mood Disorders, and Chronic Conditions With Anxiety in Opioid Patients. West. J. Nurs. Res.","DOI":"10.1177\/01939459211031988"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.mcna.2018.02.012","article-title":"Sleep Management Among Patients with Substance Use Disorders","volume":"102","author":"Chakravorty","year":"2018","journal-title":"Med. Clin. N. Am."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1080\/02791072.2014.977501","article-title":"The Prevalence of Posttraumatic Stress Disorder Symptoms among Addiction Treatment Patients with Cocaine Use Disorders","volume":"47","author":"Saunders","year":"2015","journal-title":"J. Psychoact. Drugs"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/add.15580","article-title":"Prevalence of co-occurring mental illness and substance use disorder and association with overdose: A linked data cohort study among residents of British Columbia, Canada","volume":"117","author":"Keen","year":"2022","journal-title":"Addiction"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"107707","DOI":"10.1016\/j.drugalcdep.2019.107707","article-title":"Non-fatal drug overdose after release from prison: A prospective data linkage study","volume":"206","author":"Keen","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Hedegaard, H., Curtin, S.C., and Warner, M. (2020). Suicide Mortality in the United States, 1999\u20132019. NCHS Data Brief, 1\u20138.","DOI":"10.15620\/cdc:101761"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"108041","DOI":"10.1016\/j.drugalcdep.2020.108041","article-title":"Links between suicidal intent, polysubstance use, and medical treatment after non-fatal opioid overdose","volume":"212","author":"Gicquelais","year":"2020","journal-title":"Drug Alcohol Depend."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.addbeh.2017.11.030","article-title":"Overdose and adverse drug event experiences among adult patients in the emergency department","volume":"86","author":"Bohnert","year":"2018","journal-title":"Addict. Behav."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"107612","DOI":"10.1016\/j.drugalcdep.2019.107612","article-title":"Suicidal motivations reported by opioid overdose survivors: A cross-sectional study of adults with opioid use disorder","volume":"205","author":"Connery","year":"2019","journal-title":"Drug Alcohol Depend."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jpsychires.2022.06.039","article-title":"Distinguishing clinical factors associated with unintentional overdose, suicidal ideation, and attempted suicide among opioid use disorder in-patients","volume":"153","author":"Stover","year":"2022","journal-title":"J. Psychiatr. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1056\/NEJMra1802148","article-title":"Understanding Links among Opioid Use, Overdose, and Suicide","volume":"380","author":"Bohnert","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1080\/15504263.2016.1172898","article-title":"Dual Disorders and Suicide","volume":"12","author":"Abroms","year":"2016","journal-title":"J. Dual Diagn."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.drugalcdep.2015.01.009","article-title":"Trends in dual diagnosis of severe mental illness and substance use disorders, 1996\u20132010, Israel","volume":"148","author":"Ponizovsky","year":"2015","journal-title":"Drug Alcohol Depend."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/10826084.2011.636135","article-title":"Dual diagnosis and suicide risk in a Spanish outpatient sample","volume":"47","author":"Szerman","year":"2012","journal-title":"Subst. Use Misuse"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.4088\/JCP.11m06837","article-title":"Concise Health Risk Tracking scale: A brief self-report and clinician rating of suicidal risk","volume":"72","author":"Trivedi","year":"2011","journal-title":"J. Clin. Psychiatry"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: Validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.psychres.2017.09.044","article-title":"A longitudinal investigation of the Concise Health Risk Tracking Self-Report (CHRT-SR) in suicidal patients during and after hospitalization","volume":"262","author":"Villegas","year":"2018","journal-title":"Psychiatry Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jpsychires.2015.10.004","article-title":"A clinical measure of suicidal ideation, suicidal behavior, and associated symptoms in bipolar disorder: Psychometric properties of the Concise Health Risk Tracking Self-Report (CHRT-SR)","volume":"71","author":"Ostacher","year":"2015","journal-title":"J. Psychiatr. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jpsychires.2018.03.012","article-title":"A psychometric evaluation of the Concise Health Risk Tracking Self-Report (CHRT-SR)- a measure of suicidality-in patients with stimulant use disorder","volume":"102","author":"Sanchez","year":"2018","journal-title":"J. Psychiatr. Res."},{"key":"ref_30","unstructured":"NIDA (2022, April 20). About the CTN, Available online: https:\/\/nida.nih.gov\/about-nida\/organization\/cctn\/ctn\/about-ctn."},{"key":"ref_31","unstructured":"NIDA (2022, May 20). Data Share Website: Home, Available online: https:\/\/datashare.nida.nih.gov\/."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.4088\/JCP.15m10591","article-title":"Randomized Controlled Trial Comparing Exercise to Health Education for Stimulant Use Disorder: Results From the CTN-0037 STimulant Reduction Intervention Using Dosed Exercise (STRIDE) Study","volume":"78","author":"Trivedi","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1001\/jama.2016.8914","article-title":"Effect of Patient Navigation With or Without Financial Incentives on Viral Suppression Among Hospitalized Patients With HIV Infection and Substance Use: A Randomized Clinical Trial","volume":"316","author":"Metsch","year":"2016","journal-title":"JAMA"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(17)32812-X","article-title":"Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): A multicentre, open-label, randomised controlled trial","volume":"391","author":"Lee","year":"2018","journal-title":"Lancet"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.drugalcdep.2017.04.020","article-title":"A randomized placebo-controlled trial of N-acetylcysteine for cannabis use disorder in adults","volume":"177","author":"Gray","year":"2017","journal-title":"Drug Alcohol Depend."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/ADM.0000000000000218","article-title":"Utilizing a Two-stage Design to Investigate the Safety and Potential Efficacy of Monthly Naltrexone Plus Once-daily Bupropion as a Treatment for Methamphetamine Use Disorder","volume":"10","author":"Mooney","year":"2016","journal-title":"J. Addict. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"ofab334","DOI":"10.1093\/ofid\/ofab334","article-title":"Care Facilitation Advances Movement Along the Hepatitis C Care Continuum for Persons With Human Immunodeficiency Virus, Hepatitis C, and Substance Use: A Randomized Clinical Trial (CTN-0064)","volume":"8","author":"Metsch","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1111\/add.15836","article-title":"HIV clinic-based extended-release naltrexone versus treatment as usual for people with HIV and opioid use disorder: A non-blinded, randomized non-inferiority trial","volume":"117","author":"Korthuis","year":"2022","journal-title":"Addiction"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa2020214","article-title":"Bupropion and Naltrexone in Methamphetamine Use Disorder","volume":"384","author":"Trivedi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_40","unstructured":"NIDA (2022, July 10). Protocol NIDA-CTN-0037: Stimulant Reduction Intervention Using Dosed Exercise (STRIDE), Available online: http:\/\/ctndisseminationlibrary.org\/protocols\/ctn0037.htm."},{"key":"ref_41","unstructured":"NIDA (2022, July 10). Protocol NIDA-CTN-0049: Project HOPE Hospital Visit as Oopportunity for Prevention and Engagement for HIV-Infected Drug Users, Available online: http:\/\/ctndisseminationlibrary.org\/protocols\/ctn0049.htm."},{"key":"ref_42","unstructured":"NIDA (2022, July 10). Protocol NIDA-CTN-0051: Extended-Release Naltrexone vs. Buprenorphone for Opioid Treatment (X:BOT), Available online: http:\/\/ctndisseminationlibrary.org\/protocols\/ctn0051.htm."},{"key":"ref_43","unstructured":"NIDA (2022, July 10). Protocol NIDA-CTN-0053: Achieving Cannabis Cessation- Evaluating N-Acetylcysteine Treatment (ACCENT), Available online: http:\/\/ctndisseminationlibrary.org\/protocols\/ctn0053.htm."},{"key":"ref_44","unstructured":"NIDA (2022, July 10). Protcol NIDA-CTN-0054: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT) for Methamphetamine Use Disorder, Available online: http:\/\/ctndisseminationlibrary.org\/protocols\/ctn0054.htm."},{"key":"ref_45","unstructured":"NIDA (2022, July 10). Protocol NIDA-CTN-0064: Linkage to Hepatitis C Virus (HCV) Care Among HIV\/HCV Co-infected Substance Users, Available online: http:\/\/ctndisseminationlibrary.org\/protocols\/ctn0064.htm."},{"key":"ref_46","unstructured":"NIDA (2022, July 10). Protocol NIDA-CTN-0067: Comparing Treatments for HIV-Positive Opioid Users in an Integrated Care Effectiveness Study (CHOICES: Scale-Up, Available online: http:\/\/ctndisseminationlibrary.org\/protocols\/ctn0067.htm."},{"key":"ref_47","unstructured":"NIDA (2022, July 10). Protocol NIDA-CTN-0068: Accelerated Development of Additive Pharmacotherapy Treatment (ADAPT-2) for Methamphetamine Use Disorder, Available online: http:\/\/ctndisseminationlibrary.org\/protocols\/ctn0068.htm."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Derogatis, L. (2000). Brief Symptom Inventory (BSI) 18: Administration, Scoring, and Procedures Manual, National Computer Systems. [3rd ed.].","DOI":"10.1037\/t07502-000"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0740-5472(92)90062-S","article-title":"The Fifth Edition of the Addiction Severity Index","volume":"9","author":"McLellan","year":"1992","journal-title":"J. Subst. Abuse Treat."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","article-title":"The hospital anxiety and depression scale","volume":"67","author":"Zigmond","year":"1983","journal-title":"Acta Psychiatr. Scand."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.drugpo.2013.10.015","article-title":"Unintentional opioid overdose deaths in New York City, 2005\u20132010: A place-based approach to reduce risk","volume":"25","author":"Siegler","year":"2014","journal-title":"Int. J. Drug Policy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"915","DOI":"10.2105\/AJPH.2016.303084","article-title":"A Longitudinal Study of Multiple Drug Use and Overdose Among Young People Who Inject Drugs","volume":"106","author":"Riley","year":"2016","journal-title":"Am. J. Public Health"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/pme.12777","article-title":"Development of a Risk Index for Serious Prescription Opioid-Induced Respiratory Depression or Overdose in Veterans\u2019 Health Administration Patients","volume":"16","author":"Zedler","year":"2015","journal-title":"Pain Med."},{"key":"ref_54","unstructured":"Association, A.P. (2013). Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Fifth Edition, American Psychiatric Association. [5th ed.]."},{"key":"ref_55","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): The development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"ref_56","unstructured":"SAS Institute Inc. (2014). SAS\u00ae OnDemand for Academics: User\u2019s Guide, SAS Institute Inc."},{"key":"ref_57","first-page":"6","article-title":"A Closer Look at Substance Use and Suicide","volume":"13","author":"Esang","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"ref_58","unstructured":"Brandt, L., Hu, M., Liu, Y., Castillo, F., Odom, G., Balise, R., Feaster, D., Nunes, E., and Luo, S. (2022). Risks of Overdose Events for Patients Undergoing Opioid Use Disorder Treatment, The College on Problems of Drug Dependence."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/da.22855","article-title":"The Concise Health Risk Tracking Self-Report (CHRT-SR) assessment of suicidality in depressed outpatients: A psychometric evaluation","volume":"36","author":"Rush","year":"2019","journal-title":"Depress. Anxiety"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s43045-020-00029-w","article-title":"Assessment of anxiety and depression among substance use disorder patients: A case-control study","volume":"27","author":"Mohamed","year":"2020","journal-title":"Middle East Curr. Psychiatry"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/21\/6400\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:05:26Z","timestamp":1760144726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/11\/21\/6400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,29]]},"references-count":60,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["jcm11216400"],"URL":"https:\/\/doi.org\/10.3390\/jcm11216400","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,29]]}}}